News
EVH
33.09
+1.08%
0.36
Evolent Health Price Target Cut to $44.00/Share From $45.00 by Canaccord Genuity
Dow Jones · 7h ago
Evolent Health Is Maintained at Buy by Canaccord Genuity
Dow Jones · 7h ago
Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $44
Benzinga · 7h ago
Weekly Report: what happened at EVH last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at EVH last week (0311-0315)?
Weekly Report · 03/18 09:00
Navigating 4 Analyst Ratings For Evolent Health
Four analysts have released ratings for Evolent Health in the past three months. The company is engaged in healthcare delivery and payment. The average 12-month price target for the company is $45.0. EvolENT Health's revenue growth over the past 3 months is higher than the industry average.
Benzinga · 03/15 16:00
Evolent Health Price Target Cut to $52.00/Share From $53.00 by JP Morgan
Dow Jones · 03/15 14:27
Evolent Health Is Maintained at Overweight by JP Morgan
Dow Jones · 03/15 14:27
JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $52
Benzinga · 03/15 14:17
Evolent Health (NYSE:EVH) Is Experiencing Growth In Returns On Capital
Evolent Health's (NYSE:EVH) return on capital employed is 1.5%. The company has a high rate of return, but it under-performs the Healthcare Services industry average of 6.2%. Evolent Health has generated a 168% total return over the last five years. The company is increasing its return on Capital Employed to a high level of 1.6%. It's a good sign for a company to have an expanding base of capital employed. But there are two warning signs for investors to consider.
Simply Wall St · 03/12 10:40
Weekly Report: what happened at EVH last week (0304-0308)?
Weekly Report · 03/11 09:00
Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible
Health Catalyst reported strong Q4 results, showing growth in technology and professional services revenue. The company's growth initiatives, such as its TEMS offering and next-gen data platform, are expected to drive growth and margin expansion. HCAT's long-term guidance of exceeding $100 million in EBITDA by FY28 is achievable. I recommend a buy rating for Health Catalyst.
Seeking Alpha · 03/09 09:50
Evolent Health Inc: Statement of changes in beneficial ownership of securities
Press release · 03/06 03:04
Evolent Health (EVH) Gets a Hold from Truist Financial
TipRanks · 03/05 12:26
Weekly Report: what happened at EVH last week (0226-0301)?
Weekly Report · 03/04 09:00
Evolent Health Price Target Announced at $45.00/Share by Oppenheimer
Dow Jones · 03/01 13:09
Evolent Health Initiated at Outperform by Oppenheimer
Dow Jones · 03/01 13:09
Oppenheimer Initiates Coverage On Evolent Health with Outperform Rating, Announces Price Target of $45
Benzinga · 03/01 12:59
Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know
NASDAQ · 02/27 14:55
More
Webull provides a variety of real-time EVH stock news. You can receive the latest news about Evolent Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About EVH
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers three primary solutions: specialty care management services, total cost of care management and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advance care planning services as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its total cost of care management solution enables providers to manage populations they may be accountable for under value-based contracts with payers or accountable care organizations (ACO) contracts with Centers for Medicare and Medicaid Services (CMS). Its administrative services solution includes integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.